The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Breast and Ovarian Cancer
Open accessAbstract
espite years of intensive study and substantial progress in understanding susceptibility to breast and ovarian cancer, these diseases remain important causes of death in women.However, several recent critical advances -sequencing of the human genome and the development of high-throughput techniques for identifying DNA-sequence variants, changes in copy numbers, and global expression profiles -have dramatically accelerated the pace of research aimed at preventing and curing these diseases.We review some of the important discoveries in the genetics of breast and ovarian cancer, ongoing studies to isolate additional susceptibility genes, and early work on molecular profiling involving microarrays.In the United States, 10 to 20 percent of patients with breast cancer and patients with ovarian cancer have a first-or second-degree relative with one of these diseases. 1Two major genes associated with susceptibility to breast and ovarian cancer -breast cancer susceptibility gene 1 ( BRCA1 ) and breast cancer susceptibility gene 2 ( BRCA2 ) -have been identified to date. 2,3Mutations in either of these genes confer a lifetime risk of breast cancer of between 60 and 85 percent and a lifetime risk of ovarian cancer of between 15 and 40 percent. 4,5However, mutations in these genes account for only 2 to 3 percent of all breast cancers, 6,7 and susceptibility alleles in other genes, such as TP53, PTEN, and STK11/LKB1, are even less common causes of breast and ovarian cancer (Fig. 1).The prediction that there are common DNA-sequence variants that confer a small but appreciable enhanced risk of cancer has been validated with the recent discovery of the 1100delC mutation in the cell-cycle-checkpoint kinase gene ( CHEK2 ). 9 This mutation was found in 1.1 percent of women without breast cancer, 1.4 percent of women with a personal but no family history of breast cancer, and 4.2 percent of index patients from 718 families in which two or more members had been given a diagnosis of breast cancer before the age of 60 years but in which there was no detectable BRCA1 or BRCA2 mutation.This mutation doubles the risk of breast cancer among women and increases the risk among men by a factor of 10.CHEK2, an important component of the cellular machinery that recognizes and repairs damaged DNA, is activated after phosphorylation by the checkpoint gene ATM and in turn activates BRCA1.The role of ATM mutations in the predisposition to the early onset of breast cancer remains controversial, but some missense mutations do appear to increase susceptibility to breast cancer in humans 10 and mice. 11There is convincing evidence that additional high-penetrance genes that increase susceptibility to breast cancer exist.In contrast, it has been suggested that, other than BRCA1 and BRCA2, high-penetrance genes that confer susceptibility to ovarian cancer do not exist. 12An ovarian-cancer-susceptibility locus on chromosome 3p22-25 has d susceptibility to breast and ovarian cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationDistinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationA map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
The International SNP Map Working Group, Laboratories:, C. S. H., Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., National Center for Biotechnology Information:, Marth, G., Sherry, S., et al. (2001) · Nature · doi:10.1038/35057149 · Cited by 2,977
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
Self-citationGene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Self-citationDistinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Pollack, J. R., Sørlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lonning, P. E., Tibshirani, R., Botstein, D., Børresen-Dale, A.-L., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162471999 · Cited by 1,167
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Assembly of microarrays for genome-wide measurement of DNA copy number
Snijders, A. M., Nowak, N., Segraves, R., Blackwood, S., Brown, N., Conroy, J., Hamilton, G., Hindle, A. K., Huey, B., Kimura, K., et al. (2001) · Nature Genetics · doi:10.1038/ng754 · Cited by 999
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Claus, E. B., RISCH, N. J., & Thompson, W. D. (1991) · PubMed · Cited by 911
Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
Parmigiani, G., Berry, D. A., & Aguilar, O. (1998) · The American Journal of Human Genetics · doi:10.1086/301670 · Cited by 753
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., Jablon, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362002 · Cited by 685
Self-citationBreast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Self-citationProportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors
Madigan, M. P., Ziegler, R. G., Benichou, J., Byrne, C., & Hoover, R. N. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.22.1681 · Cited by 655
Welsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Newly Identified Actions of the Vitamin D Endocrine System*
WALTERS, M. R. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-4-719 · Cited by 593
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene
Albertson, D. G., Ylstra, B., Segraves, R., Collins, C., Dairkee, S. H., Kowbel, D., Kuo, W.-L., Gray, J. W., & Pinkel, D. (2000) · Nature Genetics · doi:10.1038/75985 · Cited by 589
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Self-citationA systematic review of genetic polymorphisms and breast cancer risk.
Dunning, A., Healey, C. S., Pharoah, P., Teare, M. D., Ponder, B. A. J., & Easton, D. F. (1999) · PubMed · Cited by 539
Ford, D., Easton, D. F., & Peto, J. (1995) · Europe PMC (PubMed Central) · Cited by 528
Warner, E., Plewes, D. B., Shumak, R. S., Catzavelos, G. C., Di Prospero, L. S., Yaffe, M. J., Goel, V., Ramsay, E., Chart, P. L., Cole, D. E. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3524 · Cited by 461
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Self-citationDominant Negative ATM Mutations in Breast Cancer Families
Chenevix-Trench, G. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.205 · Cited by 376
Brekelmans, C. T. M., Seynaeve, C., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Meijers-Heijboer, E. J., Crepin, C. M. G., van Geel, A. N., Menke, M., Verhoog, L. C., van den Ouweland, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.924 · Cited by 307
Collins, C., Rommens, J. M., Kowbel, D., Godfrey, T., Tanner, M., Hwang, S.-I., Polikoff, D., Nonet, G., Cochran, J., Myambo, K., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8703 · Cited by 300
Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Stoutjesdijk, M. J., Boetes, C., Jager, G. J., Beex, L., Bult, P., Hendriks, J. H. C. L., Laheij, R. J. F., Massuger, L., van Die, L. E., Wobbes, T., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1095 · Cited by 289
Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Goffin, J., Chappuis, P. O., Wong, N., & Foulkes, W. D. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1754 · Cited by 284
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode, E. L., Dunning, A. M., Kuschel, B., Healey, C. S., Day, N., Ponder, B. A. J., Easton, D. F., & Pharoah, P. D. P. (2002) · PubMed · Cited by 252
Spring, K., Ahangari, F., Scott, S. P., Waring, P., Purdie, D. M., Chen, P. C., Hourigan, K., Ramsay, J., McKinnon, P. J., Swift, M., et al. (2002) · Nature Genetics · doi:10.1038/ng958 · Cited by 237
Armes, J. E., Trute, L., White, D., Southey, M. C., Hammet, F., Tesoriero, A. A., Hutchins, A., Dite, G. S., McCredie, M. R. E., Giles, G. G., et al. (1999) · PubMed · Cited by 236
Kudoh, K., Ramanna, M., Ravatn, R., ELKAHLOUN, A. G., Bittner, M. L., Meltzer, P. S., Trent, J. M., Dalton, W. S., & Chin, K. (2000) · PubMed · Cited by 217
Tilanus‐Linthorst, M., Verhoog, L., Obdeijn, I., Bartels, K., Menke‐Pluymers, M., Eggermont, A., Klijn, J., Meijers‐Heijboer, H., van der Kwast, T., & Brekelmans, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10666 · Cited by 195
Kainu, T., Juo, S.-H. H., Desper, R., Schäffer, A. A., Gillanders, E., Rozenblum, E., Freas-Lutz, D., Weaver, D., Stephan, D., Bailey-Wilson, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9603 · Cited by 186
Schutte, M., da Costa, L. T., Hahn, S. A., Moskaluk, C., Hoque, A. T., Rozenblum, E., Weinstein, C. L., Bittner, M., Meltzer, P. S., & Trent, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5950 · Cited by 163
Gayther, S. A., Russell, P. A., Harrington, P. A., Antoniou, A. C., Easton, D. F., & Ponder, B. A. J. (1999) · The American Journal of Human Genetics · doi:10.1086/302583 · Cited by 124
Thompson, D. J., Szabo, C. I., Mangion, J., Oldenburg, R. A., Odefrey, F., Seal, S., Barfoot, R., Kroeze‐Jansema, K., Teare, M. D., Rahman, N., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012584499 · Cited by 91
Self-citationFigeys, D., Gygi, S. P., Zhang, Y., et al. (1998) · Electrophoresis · doi:10.1002/elps.1150191045 · Cited by 74
Guðmundsson, J., Jóhannesdóttir, G., Arason, A., Bergþorsson, J. Þ., Ingvarsson, S., Egilsson, V., & Barkardottir, R. B. (1996) · PubMed Central · Cited by 70
Genetic Epidemiology of Breast and Ovarian Cancers
Newman, B. M., Millikan, R. C., & King, M. (1997) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a017948 · Cited by 55
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22
Rahman, N., Teare, M. D., Seal, S., Renard, H., Mangion, J., Cour, C., Thompson, D. J., Shugart, Y. Y., Eccles, D., Devilee, P., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203735 · Cited by 43
Self-citationChromosome 17q-Linkage Seems to be Infrequent in Icelandic Families at Risk of Breast Cancer
Barkardottir, R. B., Arason, A., Egilsson, V., Guðmundsson, J., Jónasdóttir, A., & Jóhannesdóttir, G. (1995) · Acta Oncologica · doi:10.3109/02841869509094044 · Cited by 17
Cited by
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Metadata
- Authors
- Wooster, R., & Weber, B. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-06-05
- Volume
- 348
- Issue
- 23
- Pages
- 2339-2347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2051184323
- Cited by
- 605
- References
- 54
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.